CN1303671A - Application of cinnamic acid in preparation of medicine for curing diabetes - Google Patents
Application of cinnamic acid in preparation of medicine for curing diabetes Download PDFInfo
- Publication number
- CN1303671A CN1303671A CN99115661A CN99115661A CN1303671A CN 1303671 A CN1303671 A CN 1303671A CN 99115661 A CN99115661 A CN 99115661A CN 99115661 A CN99115661 A CN 99115661A CN 1303671 A CN1303671 A CN 1303671A
- Authority
- CN
- China
- Prior art keywords
- cinnamic acid
- medicine
- preparation
- group
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an application of cinnamic acid to the preparation of medicine for curing diabetes. It possesses good therapeutic effect.
Description
The present invention relates to the application of cinnamic acid in pharmacy.
Diabetes are common chronic lifelong diseases of a kind of serious harm health, have all become serious social public health problem in each state.
And treat the medicine of diabetes at present, generally all there be the inefficacy and the bigger toxic and side effects of medicine.Therefore, develop the medicine of the treatment diabetes of new high-efficiency low-toxicity, become a research focus of current medical educational circles.
Cinnamic acid, promptly beta-phenyl acrylic acid (C6H5CH=CHCOOH) has cis and trans two kinds of isomers.Below all claim cinnamic acid.
Cinnamic acid has a wide range of applications at aspects such as food, medical industry, fine chemistry industries as a kind of important Organic Chemicals intermediate, but does not still have report as the medicine of treatment diabetes.
The objective of the invention is research provides cinnamic acid as medicine, and diabetes are had excellent curative.
Existing bibliographical information, the cinnamic acid low toxicity, safety is good.As " " rat oral LD50 is 2500mg/kg, and its mouse oral LD50 is 160mg/kg for fine chemical material and intermediate handbook publication (Xu Kexun edits the ISBN 7-5025-2005-8/TQ1008 of Chemical Industry Press)." obvious thus cinnamic acid has safety low-poison property, is suitable as medicinal application.
Experiment showed, that cinnamic acid has significant effect aspect blood sugar lowering, hence one can see that, and cinnamic acid will have excellent curative to diabetes as the medicine of active ingredient preparation.
Cinnamic acid is used to prepare medicine, can cooperate with the medicament filler of normal conventional, makes through conventional method; Can make suitable dosage form as required, as tablet, powder, granule, capsule, syrup or solution etc.With the cinnamic acid is the medicine of active ingredient, uses with oral way usually, can certainly adopt other administering mode; Its, using dosage was generally about 0.1～1000mg every day, and adult's usual amounts is 1～500mg every day, and the most frequently used dosage is 5～300mg, once a day or divide and take for several times.
Experiment embodiment cinnamic acid hypoglycemic drug effect is learned research
One experiment material
1 laboratory animal; Male mice in kunming is provided by Hunan Medical University's Experimental Animal Center, and approval number is No. 024, Hunan Province management of laboratory animal committee; Male SD rat provides the quality certification number by Hunan College of Traditional Chinese Medicine's Experimental Animal Center: 20-001 number.
2 experiment reagents;
(1) alloxan (Alloxan): available from Sigma company
(2) chain assistant urase element (STZ): available from Sigma company
(3) blood glucose meter: One Touch II-Johnson Co.
(4) positive control drug: phenformin hydrochloride tablet (JIANGZHILING PIAN) Nantong pharmacy head factory lot number: 97 1015
(5) experimental data is handled with the Instat software analysis.
Two experimental techniques and result
1. to the influence of normal mouse blood sugar
Select 50 of healthy mices, male, be divided into 5 groups at random, i.e. normal control group, basic, normal, high dosage of cinnamic acid and positive controls.Insoral group (preparation of 9mg/kg.bw distilled water), the cinnamic acid group is mixed with suspension (seeing Table 1) with smart starch, and the normal control group gavages equal-volume (0.4mmol) distilled water, irritates stomach every day once, successive administration 14 days, 2h surveys Mus tail blood glucose with blood glucose meter after the last administration.Respectively organize mice fasting 5h before getting blood.The results are shown in Table 1
Table 1 cinnamic acid is to the effect of normal mouse blood sugar
| Group | Metering mg/kg | Blood glucose mmol/L |
| The normal control group | ??0.4mol | ????4.5+0.8 |
| Positive controls | ????9 | ????3.3+0.5 |
| The cinnamic acid low dose group | ????3 | ????4.4+0.7 |
| Dosage group in the cinnamic acid | ????9 | ????4.5+0.9 |
| The cinnamic acid high dose group | ????27 | ????4.7+0.7 |
Compare P＞0.05 with the normal control group
2. to the influence of alloxan hyperglycemia model mouse blood sugar
Set up hyperglycemia model with body weight 20～24g male mouse of kunming.Animal fasting 24h (freely drinking water), give and the moulding of alloxan 50mg/kg.bw tail vein injection, fasting 5h after 7 days, eye socket venous plexus blood is surveyed blood glucose value, gets blood glucose value and is divided into the insoral group at random greater than the 10mmol/L mice, the normal control group, low dose group, middle dosage group, high dose group, positive controls.14 days fasting 5h get eye socket venous plexus blood and survey blood glucose value behind gastric infusion, observe being subjected to the influence of reagent thing to alloxan induced hyperglycemia mice fasting glucose.The results are shown in Table 2.
Table 2 cinnamic acid is to the effect of alloxan hyperglycemia model mouse blood sugar
Compare with the blank group
*P＜0.01
| Group | Metering mg/kg | Blood glucose mmol/L |
| The blank group | ??0.4mol | ????15.8+1.6 |
| Positive controls | ????9 | ????7.3+1.5 ** |
| The cinnamic acid low dose group | ????3 | ????5.1+0.7 ** |
| Dosage group in the cinnamic acid | ????9 | ????4.5+0.9 ** |
| The cinnamic acid high dose group | ????27 | ????4.1+0.9 ** |
3. chain is helped the influence of urea mycin hyperglycemia model rat blood sugar content
70 of SD rats, male, fasting 24h (freely drinking water) gives STZ60mg/kg lumbar injection, the preparation zoic model with hyperglycemia.Surplus with above-mentioned experiment 2.The results are shown in Table 3.
Table 3 cinnamic acid is to the effect of chain assistant urea mycin hyperglycemia model rat blood sugar
Compare with the blank group
*P＜0.01
| Group | Metering mg/kg | Blood glucose mmol/L |
| The blank group | ??0.4mol | ????15.6.+1.2 |
| Positive controls | ????9 | ????7.3+3.4 ** |
| The cinnamic acid low dose group | ????3 | ????5.1+1.7 ** |
| Dosage group in the cinnamic acid | ????9 | ????4.7+1.9 ** |
| The cinnamic acid high dose group | ????27 | ????4.3+1.7 ** |
Three. conclusion
By The above results as can be known, cinnamic acid has the effect of blood sugar lowering.
Claims (4)
1. cinnamic acid is used for the treatment of application in the medicine of diabetes in preparation.
2. the structure of cinnamic acid is cis or trans or cis and trans in claims 1.
3. cinnamic acid adds in the antihypelipidemic foodstuff as active ingredient in claims 1.
4. cinnamic acid adds in the blood sugar lowering medicine as active ingredient in claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99115661A CN1303671A (en) | 1999-11-26 | 1999-11-26 | Application of cinnamic acid in preparation of medicine for curing diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN99115661A CN1303671A (en) | 1999-11-26 | 1999-11-26 | Application of cinnamic acid in preparation of medicine for curing diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1303671A true CN1303671A (en) | 2001-07-18 |
Family
ID=5278592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99115661A Pending CN1303671A (en) | 1999-11-26 | 1999-11-26 | Application of cinnamic acid in preparation of medicine for curing diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1303671A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100340271C (en) * | 2005-04-04 | 2007-10-03 | 湖北省应城市人民医院 | Hypoglycemic medicine for treating diabetes and its prepn process |
| WO2009026817A1 (en) * | 2007-08-23 | 2009-03-05 | Tang Foundation For The Research Of Traditional Chinese Medicines | Compounds and composition used for inhibitting pge2 released from cmec |
| CN101084885B (en) * | 2007-06-22 | 2011-06-22 | 中国人民解放军第四军医大学 | Two sustained-release preparations containing cinnamic acid for preventing coxsackie virus and preparation technology thereof |
| CN102264362A (en) * | 2008-12-26 | 2011-11-30 | 天然恩朵技术株式会社 | Phytoestrogenic compositions for preventing or treating symptoms associated with menopause |
| CN101406466B (en) * | 2007-06-22 | 2012-01-18 | 中国人民解放军第四军医大学 | Cinnamic acid transdermal patch and preparation technique thereof |
| CN103446139A (en) * | 2013-09-03 | 2013-12-18 | 中南大学湘雅医院 | Medicine composition for treating metabolic syndrome |
| CN108452311A (en) * | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | Composition for enhancing energetic supersession and method |
| CN112770737A (en) * | 2018-06-07 | 2021-05-07 | 庆熙大学校产学协力团 | Pharmaceutical composition for preventing or treating allodynia caused by anticancer drugs |
-
1999
- 1999-11-26 CN CN99115661A patent/CN1303671A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100340271C (en) * | 2005-04-04 | 2007-10-03 | 湖北省应城市人民医院 | Hypoglycemic medicine for treating diabetes and its prepn process |
| CN101084885B (en) * | 2007-06-22 | 2011-06-22 | 中国人民解放军第四军医大学 | Two sustained-release preparations containing cinnamic acid for preventing coxsackie virus and preparation technology thereof |
| CN101406466B (en) * | 2007-06-22 | 2012-01-18 | 中国人民解放军第四军医大学 | Cinnamic acid transdermal patch and preparation technique thereof |
| WO2009026817A1 (en) * | 2007-08-23 | 2009-03-05 | Tang Foundation For The Research Of Traditional Chinese Medicines | Compounds and composition used for inhibitting pge2 released from cmec |
| CN102264362A (en) * | 2008-12-26 | 2011-11-30 | 天然恩朵技术株式会社 | Phytoestrogenic compositions for preventing or treating symptoms associated with menopause |
| CN102264362B (en) * | 2008-12-26 | 2013-10-23 | 天然恩朵技术株式会社 | Phytoestrogenic compositions for preventing or treating symptoms associated with menopause |
| CN108452311A (en) * | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | Composition for enhancing energetic supersession and method |
| CN103446139A (en) * | 2013-09-03 | 2013-12-18 | 中南大学湘雅医院 | Medicine composition for treating metabolic syndrome |
| CN112770737A (en) * | 2018-06-07 | 2021-05-07 | 庆熙大学校产学协力团 | Pharmaceutical composition for preventing or treating allodynia caused by anticancer drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alam et al. | Efficacy of Spirulina (Tahlab) in patients of type 2 diabetes mellitus (Ziabetus Shakri): A randomized controlled trial | |
| CN101842103A (en) | The unit dose that is used for brain health | |
| CN103637185B (en) | Nervonic acid composition | |
| CN1303671A (en) | Application of cinnamic acid in preparation of medicine for curing diabetes | |
| CN105106577B (en) | A kind of Chinese medicine composition of the treatment diabetes containing rose | |
| Hartung | KLINISCHE ERFAHRUNGEN MIT ALFENTANIL ZUR'BALANCED ANESTHESIA'BEI OBERBAUCH-EINGRIFFEN | |
| Dickerson | Warfarin resistance and enteral tube feeding: a vitamin K–independent interaction | |
| CN1303672A (en) | Application of cinnamate in preparation of medicine for curing diabetes | |
| JP2013535415A (en) | Use of deuterium-reduced water for the treatment of insulin resistance | |
| CN108186631A (en) | A kind of pharmaceutical composition and its preparation method and application | |
| Ignacimuthu et al. | EFFECT OF LEAF EXTRACT OF ZlZYPHUS JUJUBA ON DIABETIC RATS | |
| Drewe et al. | Effect of intravenous infusions of thiamine on the disposition kinetics of thiamine and its pyrophosphate | |
| CN114916604A (en) | Gel candy with health care function | |
| Jung et al. | Weight reduction effects of yeast hydrolysate below 10 kDa on obese young women | |
| JP2014181232A (en) | Blood sugar level elevation inhibitor of capsicum frutescens fermentation product using aspergillusoryzae | |
| CN110179860A (en) | A kind of drug of anti-epileptic, preparation method and the usage | |
| US8017594B2 (en) | Agent against psychosocial stresses | |
| CN103263405B (en) | Medicinal composition for treating diabetes, and its application | |
| CN117338772B (en) | Pharmaceutical composition and application thereof in preparation of drugs for preventing and/or treating major depressive disorder | |
| Bao et al. | Griflola frondosa (GF) produces significant antidepressant effects involving AMPA receptor activation in mice | |
| EP2796143B1 (en) | Pharmaceutical homeopathic medication for reducing weight | |
| CN108371712A (en) | Caffeine combines the purposes prepared in AD drugs with PPAR gamma agonists | |
| CN1281229C (en) | Eye drop and its preparation | |
| CN100346780C (en) | Compound preparation for prevention and treatment adiposis and its prepn. method | |
| Windle et al. | Neutropenia associated with metronidazole. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |